Blenrep (Belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma

CAR-T Digest - August 2020

24 July 2025: Blenrep (Belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma

Blenrep has been approved in the EU for use with BVd or BPd regimens to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy
The approval is based on strong results from the Phase 3 DREAMM-7 and DREAMM-8 trials, where Blenrep combinations significantly improved progression-free and overall survival compared to standard treatments
In DREAMM-7, median PFS nearly tripled (36.6 vs. 13.4 months), and risk of death dropped by 43%. DREAMM-8 also showed a major PFS advantage
Blenrep, a first-in-class anti-BCMA ADC, demonstrated benefits across diverse patient groups, including those with high-risk features and lenalidomide-refractory disease
As a first-in-class anti-BCMA ADC, Blenrep delivered meaningful results even in hard-to-treat patients, marking its sixth global approval, with more expected soon